Glucagon-like peptide-1 (GLP-1) analogs have emerged as a compelling therapeutic target for managing metabolic syndromes. These naturally occurring hormones are secreted by the gut in response to meal intake, stimulating insulin release and suppressing glucagon output. GLP-1 agents exhibit promising therapeutic efficacy in treating type 2 diabetes